Elan

Multinationals fret over ruling on intellectual property sale

Perrigo court case and ruling over €1.64bn tax bill has far-reaching implications

Perrigo loses action to overturn €1.64bn Irish tax assessment

Action brought by drug firm against Revenue closely watched for implications beyond case

Perrigo mulls over appeal path to pursue on €1.64bn tax bill

US pharma giant says it is disappointed by High Court judgment

Fountain closes third life sciences fund after raising €125m

Group eyeing up to 10 investments, mostly in therapeutics and medical device sectors

High Court to rule on €1.64bn Perrigo tax case next week

Judgment could have major implications well beyond the drug company

UDG reinstates dividend, guidance despite ongoing Covid-19 uncertainty

Company says third quarter saw drop in revenue as restrictions hit business

Revenue says Perrigo is no ‘sacrificial victim’ over €1.6bn tax bill

Drug company not being ‘singled out’ in dispute over tax assessment, High Court told

Revenue tells court it was entitled to raise €1.64bn tax assessment against Perrigo

Tax collector maintains Perrigo owes the money because of its 2013 purchase of Elan

Perrigo tells court of ‘very high level of unfairness’ in €1.64bn tax bill

Pharma group challenging ‘surprise’ Revenue assessment in hearing via video link

Perrigo’s High Court challenge to €1.64bn tax bill to be heard remotely

US drug company case to be heard via video link due to Covid-19 courtroom restrictions

Revenue faces US drug company Perrigo over disputed €1.64bn tax bill

Irish tax authorities argue sale of drug for MS should have been treated as capital gain

Perrigo has ‘better than 50% chance’ of winning Irish tax case

US analyst RBC upbeat about High Court challenge to €1.64bn charge over Tysabri

Roll up, roll up: capitalism will drive cannabis legalisation in Ireland

Legalisation is coming, no matter what Irish policymakers may say now

Perrigo criticises Revenue move to reap back tax of €1.64bn

Tax bill linked to sale by Elan of its stake in multiple sclerosis drug Tysabri in 2013

RBC backs Perrigo over €1.6bn tax demand

Perrigo has repeatedly argued it will defend its position in the tax case, and denies Elan underpaid tax on the Tysabri deal

Perrigo files for judicial review of €1.6bn Revenue tax bill

Revenue should not have issued notice of amended assessment of liability, firm says

Canadian pharma company appoints Dublin man to lead new Europe operation

Theratechnologies has appointed Conor Walshe to the role of general manager

UDG Healthcare appoints two non-executive directors to board

Peter Chambré and Shane Cooke to take up roles with services provider on February 1st

Perrigo appeals €1.6bn Revenue tax demand

Pharma group understood to have filed documents to contest assessment

Perrigo shares rise as deadline for appealing €1.6bn Irish tax bill nears

Listed pharmaceutical giant has signalled its intention to appeal Revenue’s tax assessment

Government will fight to support Apple, but Perrigo must battle alone

Cliff Taylor: Contrasting approaches to tax bills show the delicate balance Ireland must strike

Shares in Perrigo slump to 9-year low

Company confirmed it faces Revenue demand for €1.64bn in back taxes

The terrible irony of Perrigo’s tax planning

Revenue’s activist approach has not gone unnoticed

What’s the massive Perrigo tax bill all about?

Cliff Taylor answers all your questions

Am I too late to claim against losses on Elan and Waterford Crystal?

Losses must be declared for Revenue to track them if they are being offset against gains

What next for Séamus Mulligan?

Entrepreneur might turn attention to Maynooth University cancer therapy spinout

Perrigo takes 12-year lease on 45,000sq ft at Hogan Place

New €20m six-storey block in Dublin 2 has parking for 40 cars and 56 bicycle spaces

Wild Geese: ‘Cities like Cape Town and Nairobi are already world-class innovation hubs’

Aisling Quirke’s entrepreneurial instinct found a natural home among fintech opportunities in Africa

Taoiseach defends relationship with chair of firm that HSE chief has joined

Varadkar backs Minister’s consent granted to O’Brien to take up board role at US firm

Alkermes secures US watchdog U-turn on depression drug

Food and Drug Administration accepts filing from Irish pharma group fortnight after refusal

Malin CEO Kelly Martin becomes interim chief of Novan

Martin will juggle his time between Malin and Novan

Alkermes executives take a hit on pay package

Irish-domiciled biopharma group reported 31% rise in sales last year

Quest to cure Alzheimer’s disease exhibits symptoms of failure

Failed drug trials have led some scientists and Big Pharma executives to doubt the central theory behind its cause

Perrigo to review options for multiple sclerosis drug Tysabri

CEO John Hendrickson says drug faces increased competition and potential for wider use has failed to materialise

Me & My Money: Paul Galvin, owner of Galvin Tullamore

‘I’m conscious of supporting independent business, they are the backbone of the economy’

Malin to invest up to €30m in Poseida Therapeutics

Irish-listed Malin to take a 31 per cent stake in US-based human therapeutics firm

Perrigo executives head for Israel in battle against Mylan

CEO Joe Papa and CFOJudy Brown hope to persuade Israeli holders of 10% of company not to accept takeover offer

Life sciences investment group Malin loses €9.6m in first half

Company reported its loss and revenue from investments at €2.5m in maiden set of results

Perrigo files lawsuit against suitor Mylan

Irish pharma company claims Mylan’s $27bn offer overstates potential synergies and makes false claims

Cantillon: Don’t expect dividends in Mylan offer

The company looking to buy Perrigo has a stated policy of not paying dividends

YOU MAY ALSO LIKE...

The Irish Times ePaper

Stardust

Inquests into the nightclub fire that led to the deaths of 48 people

Common Ground

How does a post-Brexit world shape the identity and relationship of these islands